Joint Accreditation for Interprofessional Continuing Education (Joint Accreditation) offers organizations the opportunity to be simultaneously accredited to provide medical, nursing, pharmacy, and optometry continuing education activities through a single, unified application process, fee structure, and set of accreditation standards.
Joint Accreditation originally began by focusing on CME, CNE, and CPE. This meant collaboration across these groups:
The American Academy of PAs (AAPA) and the Association of Regulatory Boards of Optometry's Council on Optometric Practitioner Education (ARBO/COPE) have recently joined the Joint Accreditation collaboration. This growing collaboration will help to advance the vision of interprofessional continuing education (IPCE).
Interprofessional continuing education (IPCE) is when members from two or more professions learn with, from, and about each other to enable effective collaboration and improve health outcomes.
Question for the week: What is the difference between implicit vs. explicit learning?
Implicit learning involves a process where people acquire knowledge of new information through exposure (a passive process)
Explicit learning involves a process where people seek out information, find it, and receive instruction (either actively or passively)
Implicit learning is acquisition of knowledge about the underlying structure of a complex stimulus environment by a process which takes place naturally, simply and without conscious operations. Explicit learning is a more conscious operation where the individual makes and tests hypotheses in a search for structure. Knowledge attainment can thus take place implicitly (a nonconscious and automatic abstraction of the structural nature of the material arrived at from experience of instances), explicitly through selective learning (Nick C. Ellis)
Don't miss the MIT paper written by Emile Bruneau titled, "Implicit vs. Explicit Learning Activity."
For 2017, the Quality Payment Program (QPP) will calculate 2017 MIPS Performance accordingly:
Let's take a look at some of the "high" weighted improvement activities:
Engagement of new Medicaid patients and follow-up
Subcategory: Achieving Health Equity
Participation in CAHPS or other supplemental questionnaire
Subcategory: Patient Safety And Practice Assessment
Provide 24/7 access to eligible clinicians or groups who have real-time access to patient's medical record
Subcategory: Expanded Practice Access
Use of QCDR for feedback reports that incorporate population health
Subcategory: Population Management
Oncology groups participating in the Oncology Care Model (OCM) are scored based on the requirements of participating in the APM.
Before diving into government health policy documents around Medicare or Medicaid, be sure to familiarize yourself with some of these acronyms (this is a short, basic list):
ACA: Affordable Care Act
AHIP: America’s Health Insurance Plans
APM: Alternative Payment Model
CMS: Centers for Medicare and Medicaid Services
EHR: Electronic Health Record
GAO: Government Accountability Office
HCC: Hierarchical Condition Category
HCP LAN: Health Care Payment Learning and Action Network
Health IT: Health Information Technology
HMO: Health Maintenance Organization
HMOPOS: Health Maintenance Organization Point of Service
ICD-10: International Classification of Diseases
MA: Medicare Advantage
MACRA: Medicare Access and CHIP Reauthorization Act of 2015
MAO: Medicare Advantage Organization
MedPAC: Medicare Payment and Advisory Committee
MIPS: Merit-based Incentive Payment System
MLR: Medical Loss Ratio
MMA: Medicare Prescription Drug, Improvement and Modernization Act of 2003
MSA: Medical Savings Account
OIG: Office of Inspector General
PFFS: Private Fee-for-Service
PFS: Physician Fee Schedule
PPO: Preferred Provider Organization
QPP: Quality Payment Program
SNP: Special Needs Plans
Registration for the 2018 Alliance Annual Conference is open, so don't miss this opportunity to connect with CME and CE professionals in Orlando, Florida, January 20-23, 2018.
More than 83 concurrent sessions organized by tracks to help you navigate and select the sessions that best match your needs and interests. Attend expert and peer-led learning on a broad range of topics, including: educational design, patient-centered and interprofessional education and improving patient outcomes.
In partnership with the Global Alliance for Medical Education (GAME), the Alliance Annual Conference will include a conference track focused on the needs of the international learner, how they are similar and different from those we face domestically.
Learn more and register here:
If you enjoy Twitter chats, be sure to mark the online pathology journal club #pathJC. Follow @pathJC and read up on the upcoming topics here: https://pathjc.wordpress.com/
The next #pathJC is on Nov 28 at 9 pm ET. The topic is "Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology"
You can read ahead: American Journal of Surgical Pathology
New to Twitter? Learn about Twitter Chats.
CMS just announced "Meaningful Measures" and "Patients Over Paperwork."
Here are a few excerpts from the statement made by CMS Administrator Seema Verma at the Health Care Payment Learning and Action Network (LAN) Fall Summit:
CMS announced our new initiative “Patients Over Paperwork” to address regulatory burden. This is an effort to go through all of our regulations to reduce burden. Because when burdensome regulations no longer advance the goal of patients first, we must improve or eliminate them.
That’s a lot of provider time, money, and resources focused on paperwork instead of patients.
We have too many measures. We are measuring process and not outcomes.
That’s why we’re revising current quality measures across all programs to ensure that measure sets are streamlined, outcomes-based, and meaningful to doctors and patients. This includes a review of the Hospital Star Rating program. And, we’re announcing today our new comprehensive initiative, "Meaningful Measures.”
“Meaningful Measures” takes a new approach to quality measures to reduce the burden of reporting on all providers. It draws on advice and input from the LAN as well as the National Academies of Medicine, the Core Quality Measures Collaborative, and the National Quality Forum. Continued input from the LAN will be critical in this effort.
Meaningful Measures will involve only assessing those core issues that are the most vital to providing high-quality care and improving patient outcomes.
Patients Over Paperwork, Meaningful Measures, and the new direction for the Innovation Center, are just three of our recent efforts to improve the health care system.
We all probably know someone who has been deeply affected by breast cancer. While breast cancer remains the most common type of cancer diagnosed among women, there are millions of survivors living in the United States. Many of them provide support, hope, and encouragement to newly-diagnosed patients.
In 2017, we also saw several breast cancer drug receive approvals by the FDA:
FDA approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. September 28, 2017
FDA approved neratinib (NERLYNX, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. July 17, 2017
FDA granted regular approval to palbociclib (IBRANCE, Pfizer Inc.) for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women. March 31, 2017
FDA approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. March 13, 2017
In May, the FDA approved an immunotherapy (pembrolizumab) for any "unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options."
FDA granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. May 23, 2017
CDC launched Bring Your Brave in 2015 to provide information about breast cancer to women younger than age 45. The Bring Your Brave campaign provides information about breast cancer to women younger than age 45 by sharing real stories about young women whose lives have been affected by breast cancer.
Today (Aug 1) is known as #WorldLungCancerDay
Lung cancer continues to be one of the most common cancers worldwide, claiming more lives yearly than breast, colon and prostate cancers combined. It is estimated that lung cancer accounts for nearly one in five cancer deaths globally. In 2012, there were 1.8 million newly diagnosed cases of lung cancer alone.
Join the conversation about lung cancer: #WorldLungCancerDay
I enjoyed reading this recent NEJM Catalyst article titled, "New Physicians Will Need Business School Skills." The author begins with a phrase that I encounter all the time:
“Business of medicine” issues are now forefront in the minds of most physicians.
Fundamental business and leadership training must focus on:
The authors of the article propose a very simple concept (easy to implement if your medical school is also linked to a business school):
We propose that medical schools, in conjunction with business school faculty, develop an interdisciplinary four-week clinical rotation during the fourth year of medical school. In our view, the best learning experiences would be project-based, combining components of didactic teaching sessions and hands-on experience. The goal of the four-week course would be for the student to identify and solve real problems facing the school’s hospitals and clinics.
Why limit these types of project-based learning experiences to 4th-year medical students? This should be incorporated into the worlds of GME and CME.
The authors also note the importance of achieving operational efficiencies:
Health care is too diverse across geographies and too fragmented in its structure and reimbursement methodology for this to be done exclusively by management consultants or health plan administrators.
While I love the idea of an interdisciplinary “business of medicine” elective for 4th year medical students, I also hope that more hospitals and health systems will invest in developing these types of valuable education programs for their practicing clinicians.
Sign up to receive updates: